// App-Quantinova.ai

THU0294 (2018) : 5-year efficacy and safety of apremilast treatment in subjects with psoriatic arthritis: pooled analysis of the palace studies

Researchers

Presenter

  • A. Kavanaugh

Principal Investigators

  • D.D. Gladman

  • C.J. Edwards

  • G. Schett

  • B. Guerette

  • N. Delev

  • L. Teng

  • M. Paris

  • P.J. Mease

Medical Centers

  • University of California, San Diego School of Medicine, La Jolla, CA

  • Krembil Research Institute, Toronto Western Hospital, Toronto, Canada

  • University of Southampton, Southampton, UK

  • Friedrich-Alexander-Universität Erlangen, Nürnberg und Universitätsklinikum Erlangen, Erlangen, Germany

  • Celgene Corporation, Summit, NJ

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

Locations

  • United States

  • Canada

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbott

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved